Schizophrenia Clinical Trials in Bryant, AR

About Schizophrenia Clinical Trials in Bryant

Schizophrenia is a chronic brain disorder affecting approximately 2.8 million US adults, characterized by hallucinations, delusions, disorganized thinking, and cognitive difficulties. While current treatments rely primarily on first- and second-generation antipsychotics (risperidone, olanzapine, clozapine), many patients experience incomplete symptom relief or significant side effects. Clinical trials are testing novel mechanisms including muscarinic receptor agonists (like KarXT/xanomeline-trospium), trace amine-associated receptor 1 (TAAR1) agonists, glutamate modulators, and long-acting injectable formulations. Treatment-resistant schizophrenia remains a major focus area, with trials seeking patients who have not adequately responded to standard antipsychotic therapy.

There are currently 3 schizophrenia clinical trials recruiting participants in Bryant, AR. These studies are seeking a combined 2,384 participants. Research is being sponsored by Bristol-Myers Squibb, Neurocrine Biosciences. Clinical trial participation is free and participants receive study-related medical care at no cost.